Ashwagandha (Withania somnifera): The Neuroscience Behind Its Cognitive and Anxiolytic Effects

Medical disclaimer: This article is written for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Ashwagandha interacts with several drug classes and affects thyroid and adrenal function. Consult a qualified healthcare professional before starting any supplementation protocol, particularly if you are taking prescription medications, have a thyroid condition, or are pregnant.

Introduction: When Ayurveda Meets Randomised Controlled Trials

Most adaptogens carry the weight of centuries of traditional use but thin clinical evidence. Ashwagandha — Withania somnifera — is one of the few exceptions. Over the past fifteen years a body of well-designed randomised controlled trials has accumulated around this root, supporting measurable reductions in perceived stress and serum cortisol, improvements in working memory and reaction time, and enhancements in sleep architecture. That evidence base, combined with increasingly well-characterised mechanisms of action, places ashwagandha in a separate category from most nootropic supplements marketed under the adaptogens banner.

This article examines the biology in depth: what ashwagandha's active compounds actually do at receptor, enzyme, and gene-expression level; what the most relevant trials demonstrated; how cortisol reduction connects to hippocampal protection; and how to translate the evidence into a rational dosing approach.

Botanical Context: Withania somnifera and Its Standardised Extracts

Withania somnifera is a member of the Solanaceae (nightshade) family — the same broad family as tomatoes, capsicum, and tobacco, which explains why it contains steroidal lactone scaffolds structurally distinct from most other botanicals. The plant is a small shrub native to the drier regions of India, North Africa, and the Mediterranean, and has been a cornerstone of Ayurvedic medicine for at least 3,000 years, where it is classified as a rasayana — a substance said to promote longevity and vitality.

Modern extraction technology has produced two dominant standardised forms that appear repeatedly in clinical literature:

KSM-66 is a full-spectrum extract prepared exclusively from the root, using a proprietary milk-based extraction process that has been used in Ayurvedic preparations historically. It is standardised to a minimum of 5% withanolide glycosides (often stated as ≥5% total withanolides). Because only root material is used, KSM-66 is relatively higher in withanolide A and lower in withaferin A — an important distinction for safety profiling (discussed in the hepatotoxicity section below).

Sensoril is derived from both root and leaf, yielding a different constituent ratio. It contains higher concentrations of withaferin A and oligosaccharides, and is standardised to ≥10% withanolide glycosides with ≥32% oligosaccharides. The leaf fraction increases bioactive potency in some respects but also brings a higher withaferin A load, which is the compound most associated with the rare adverse hepatic events in the literature.

For practical supplementation purposes, KSM-66 has the broadest clinical trial base and the more conservative safety profile for long-term use. Most of the landmark trials cited in this article used KSM-66 at 300–600 mg daily.

Active Constituents: Chemistry That Drives the Pharmacology

Ashwagandha's biological activity derives from several overlapping compound classes:

Withanolides are naturally occurring steroidal lactones — specifically C-28 ergostane-type steroids with a six-membered lactone ring. Withanolide A is considered the primary bioactive withanolide in root extracts. It modulates GABA-A receptor function (detailed below) and has been shown to promote axon and dendrite growth in cultured cortical neurons. Withaferin A, more concentrated in leaf, is a potent NF-κB inhibitor with pro-apoptotic activity in cancer cell lines, but at doses achievable from supplementation it also contributes anti-inflammatory signalling that may reduce neuroinflammatory anxiety pathways.

Withanosides — glycosylated withanolides — include withanolide glycosides IV and V. Withanosides have been implicated in stimulation of axonogenesis and synaptic reconstruction in animal models of neurodegenerative disease, and are proposed to contribute to the neurotrophic and memory-supporting effects of the whole extract.

Sitoindosides VII–X are glycowithanolides that demonstrate antioxidant activity in the brain and have shown nootropic effects in rodent passive avoidance paradigms. They are thought to act partly by enhancing superoxide dismutase and catalase activity in the frontal cortex and striatum, regions particularly vulnerable to oxidative stress during psychological stress exposure.

Alkaloids (isopelletierine, anaferine) and saponins (withasomnine) complete the bioactive profile, though these contribute less to the anxiolytic and cognitive mechanisms compared to the withanolide fraction.

The steroidal lactone scaffold gives withanolides a structural similarity to neurosteroids — endogenous molecules that directly modulate ligand-gated ion channels, including GABA-A receptors. This structural kinship underlies one of the most mechanistically compelling aspects of ashwagandha pharmacology.

For an in-depth look at how similar standardised plant constituents are evaluated in research contexts, explore the research compendium at RetaLABS Research, which aggregates evidence-based profiles across adaptogenic and nootropic compounds.

Anxiolytic Mechanisms: Four Convergent Pathways

1. GABA-A Receptor Partial Agonism

The most direct neurochemical mechanism linking ashwagandha to anxiolysis is partial agonism at GABA-A receptors. A 2010 study by Mehta and colleagues screened withanolides for their ability to bind and modulate GABA-A receptor subtypes using tritium-labelled muscimol and electrophysiology in Xenopus oocytes expressing recombinant receptor subunits. Withanolide A and several sitoindosides demonstrated positive allosteric modulation at GABA-A receptors containing the α1 subunit — effectively mimicking the anxiolytic mechanism of benzodiazepines, but with partial rather than full agonism at the receptor site.

This distinction matters clinically. Full GABA-A agonists (benzodiazepines) produce tolerance, dependence, and cognitive suppression at moderate doses. Partial agonism produces anxiolysis with less sedation, no documented dependence physiology, and — critically — does not impair working memory in the way that benzodiazepine use does. This profile aligns with what RCTs actually measure: reduced anxiety without the cognitive blunting that would make ashwagandha counterproductive as a nootropic.

The GABA-A mechanism also provides a mechanistic explanation for the sleep-promoting effects observed in clinical trials — GABA-A modulation at α1 subunits is closely tied to sleep onset and slow-wave sleep depth, which matches the Langade 2019 findings described below.

2. HPA Axis Modulation — Cortisol and DHEA-S

The hypothalamic-pituitary-adrenal (HPA) axis is the primary physiological stress response system. Chronic activation of this axis maintains elevated serum cortisol, which over weeks and months produces progressive neurological consequences — the best characterised being hippocampal dendrite retraction and impaired neurogenesis.

Ashwagandha modulates HPA axis activity through at least two documented routes. First, withanolides appear to inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme that regenerates active cortisol from cortisone within peripheral tissues and the brain. By limiting this local cortisol amplification, withanolides reduce effective cortisol exposure in corticoid-sensitive tissues without suppressing the adrenal axis at its origin — which makes the effect more nuanced and less likely to produce adrenal suppression than exogenous glucocorticoid administration.

Second, ashwagandha supplementation consistently raises DHEA-S (dehydroepiandrosterone sulphate) in clinical trials. DHEA-S is a neurosteroid produced in the adrenal cortex and to a lesser extent in the brain itself. It is a negative modulator of GABA-A receptors containing the δ subunit (opposing the anxiety-promoting effects of cortisol at this receptor class) and a positive modulator of NMDA receptor function. Rising DHEA-S during ashwagandha supplementation functions as a biological counterbalance — simultaneously supporting alertness and reducing anxiety sensitivity while the falling cortisol reduces allostatic load.

3. NF-κB Pathway and Inflammatory Anxiety

There is growing recognition that anxiety disorders — particularly chronic, generalised forms — involve peripheral and central inflammatory signalling. IL-6, IL-1β, and TNF-α are elevated in individuals with high trait anxiety, and NF-κB is the master transcription factor driving expression of these cytokines. Withaferin A is a potent inhibitor of NF-κB signalling, acting by directly binding IκB kinase beta (IKKβ) and preventing IκBα phosphorylation and degradation.

In the brain, NF-κB-driven neuroinflammation in the prefrontal cortex, amygdala, and hippocampus contributes to both hyperreactive threat detection (anxiety) and impaired cognitive flexibility. By dampening this inflammatory tone, ashwagandha may reduce anxiety through a route entirely distinct from the GABAergic and HPA mechanisms — which could explain why the anxiolytic effect is sustained over weeks rather than occurring acutely.

4. Interaction with the Monoamine System

Animal studies have documented ashwagandha's ability to modulate serotonin receptor expression in the hippocampus and increase dopaminergic transmission in limbic regions. While direct human evidence on these pathways remains sparse, the anxiolytic effects observed in chronic stress models are partially attenuated by serotonin receptor blockade in rodents, suggesting monoaminergic contribution that complements the GABAergic primary mechanism.

Key Anxiety and Stress Trials

Chandrasekhar et al. (2012) remains the most widely cited ashwagandha RCT. In this 60-day double-blind, randomised, placebo-controlled trial, 64 adults with a history of chronic stress received either 300 mg twice daily of KSM-66 full-spectrum root extract or placebo. Primary endpoints included the Perceived Stress Scale (PSS), serum cortisol, and the General Health Questionnaire-28. The KSM-66 group showed a 27.9% reduction in serum cortisol versus 7.9% in the placebo arm — a statistically significant and clinically meaningful difference. PSS scores fell substantially more in the treatment group, and Pittsburgh Sleep Quality Index (PSQI) scores improved significantly, with participants reporting faster sleep onset and better daytime functioning. Safety was excellent; no clinically significant adverse events were reported.

Pratte et al. (2014) conducted a 90-day KSM-66 trial in a stressed adult population and corroborated the cortisol reduction, additionally documenting improvements in the Fatigue Severity Scale — suggesting that HPA axis downregulation translated into subjective energy and recovery benefits beyond simple anxiety reduction.

Langade et al. (2019) specifically targeted sleep in a 10-week RCT with 600 mg KSM-66 nightly. Polysomnography-verified outcomes demonstrated improvements in sleep onset latency, sleep efficiency, total sleep time, and subjective sleep quality compared to placebo. Given that disordered sleep is both a cause and consequence of HPA axis dysregulation, these findings reinforce the mechanistic picture: ashwagandha addresses the cortisol-sleep-cognitive performance feedback loop at multiple points simultaneously.

Cognitive Effects: Evidence and Mechanisms

Clinical Trial Evidence

Choudhary et al. (2017) enrolled 50 cognitively healthy adults in an 8-week RCT using 300 mg KSM-66 twice daily. The assessment battery included the Wechsler Adult Intelligence Scale IV (WAIS-IV) — specifically reaction time, digit span (a measure of working memory), and processing speed — alongside the Stroop Colour-Word test for executive function and cognitive inhibition. Compared to placebo, the ashwagandha group showed statistically significant improvements across all cognitive domains tested. Notably, the effect on digit span (immediate and delayed) points to hippocampal-dependent memory improvements rather than purely attention or arousal effects.

Calabrese et al. (2014) used a 500 mg root extract in healthy adults over 14 days and found significant improvements in reaction time, spatial working memory, and a psychomotor tracking task. The 14-day timeline is shorter than would be expected for full HPA axis normalisation, suggesting some component of the cognitive benefit operates on a faster timescale — possibly through GABAergic effects reducing anxious interference with memory encoding, or through acute antioxidant actions at the hippocampal level.

Hypothesised Mechanisms

BDNF modulation: BDNF (brain-derived neurotrophic factor) is the primary driver of synaptic plasticity, neurogenesis in the hippocampal dentate gyrus, and long-term potentiation. Animal data consistently shows ashwagandha root extract increasing BDNF expression in the hippocampus and prefrontal cortex. The pathway is likely indirect — cortisol suppresses BDNF transcription via glucocorticoid receptor activation, so reducing chronic cortisol exposure disinhibits BDNF production. For a deeper exploration of BDNF's central role in cognitive resilience, see our comprehensive BDNF guide.

Acetylcholinesterase inhibition: Several withanolides, including withanolide A and withanolide B, demonstrate dose-dependent inhibition of acetylcholinesterase (AChE) in vitro — the enzyme that breaks down acetylcholine at synapses. By extending the presence of acetylcholine at muscarinic and nicotinic receptors in the hippocampus and prefrontal cortex, this mechanism could directly enhance encoding of new memories and speed of information processing, in a manner mechanistically similar (though far less potent) to pharmaceutical AChE inhibitors used in dementia management. This cholinergic contribution may explain why cognitive effects appear earlier in some trials than the cortisol-normalisation timeline would predict.

Hippocampal antioxidant protection: The sitoindosides fraction enhances glutathione, catalase, and superoxide dismutase activity in hippocampal tissue under oxidative stress conditions. Stress-induced oxidative damage to CA1 and CA3 pyramidal neurons is well-documented, and mitigating this damage preserves the structural substrate for memory consolidation.

Cortisol, the Hippocampus, and the Memory Connection

This mechanism deserves extended treatment because it connects the anxiolytic and cognitive evidence in a single coherent framework. Bruce McEwen's landmark 2007 review in Physiological Reviews synthesised decades of work showing that chronic elevated glucocorticoids cause measurable retraction of apical dendrites in CA3 hippocampal pyramidal neurons, reduce neurogenesis in the dentate gyrus, and impair long-term potentiation — the synaptic mechanism underlying memory formation. These structural changes are not permanent at the early stages but become increasingly entrenched with prolonged stress exposure.

The practical implication: any intervention that durably reduces cortisol by the magnitude seen in the Chandrasekhar 2012 trial (approximately 28%) would, according to McEwen's model, create conditions permissive of hippocampal dendritic recovery and renewed neurogenesis. The 8-week timeline used by Choudhary 2017 is precisely the duration over which measurable dendritic remodelling occurs in animal models of stress reversal.

DHEA-S amplifies this neuroprotective picture. As a neurosteroid, DHEA-S functions as an endogenous neuroprotective agent: it directly opposes glucocorticoid-induced neuronal atrophy in hippocampal cell culture, and epidemiological data link higher DHEA-S levels in older adults with better preserved declarative memory. Ashwagandha's simultaneous cortisol suppression and DHEA-S elevation thus produces a dual-action hippocampal protection effect.

Athletic Performance and the Cognitive Testosterone Connection

Wankhede et al. (2015) reported a 15% increase in serum testosterone and significant improvements in muscle strength and recovery in resistance-trained males supplementing 300 mg KSM-66 twice daily for 8 weeks. While this is typically discussed in sports nutrition contexts, the cognitive implications are underappreciated.

Testosterone receptors are distributed throughout the prefrontal cortex, hippocampus, and amygdala. Testosterone drives BDNF expression, promotes dendritic spine density in hippocampal pyramidal neurons, and modulates dopaminergic signalling in circuits governing motivation and working memory. The VO2max improvements observed in ashwagandha trials also intersect with cognition: aerobic capacity improvements are among the most robust predictors of BDNF elevation, creating a cascade from physical fitness to synaptic plasticity. This makes ashwagandha potentially relevant not just as a direct cognitive agent but as a compound that optimises the hormonal and metabolic environment in which cognition operates.

For context on how cognitive performance synergises with stimulant compounds, see our review of caffeine and L-theanine as a cognitive pair.

Safety Profile and Contraindications

Ashwagandha is generally well-tolerated across the clinical trial evidence base. The most commonly reported adverse events are mild and gastrointestinal — nausea, loose stools, and stomach discomfort — and these are significantly reduced by taking the supplement with food.

Hepatotoxicity: Rare case reports of liver injury, including cholestatic hepatitis and fulminant hepatic failure, have emerged over the past decade. When these cases have been characterised, the supplement involved was typically either an unspecified or leaf-containing extract rather than a pure root preparation. Withaferin A — found at higher concentrations in leaf — demonstrates hepatocyte toxicity in cell culture above a threshold concentration. This is a strong argument for preferring KSM-66 (root-only, lower withaferin A) over leaf-containing or unspecified products, particularly for long-term use. Individuals with pre-existing liver disease should avoid ashwagandha entirely.

Thyroid stimulation: Multiple human trials report increases in T3 and T4 thyroid hormone levels, probably through enhanced thyroid-stimulating hormone (TSH) sensitivity or direct thyroid peroxidase activity. This is clinically meaningful in individuals with hyperthyroidism or Graves' disease, where ashwagandha is contraindicated. For individuals with hypothyroidism, this thyroid-stimulating effect may be advantageous — but should only be explored under medical supervision with monitoring of thyroid panels.

Drug interactions: The GABAergic mechanism creates a pharmacodynamic interaction risk with benzodiazepines, Z-drugs, and other central nervous system depressants — additive sedation is theoretically possible. Thyroid hormone supplementation dosing may require adjustment with concurrent ashwagandha use. The cortisol-lowering effect should be considered in patients on corticosteroid therapy.

Pregnancy: Withania somnifera has abortifacient activity documented in animal models and is contraindicated in pregnancy.

Dosing Protocol

The clinical evidence converges on a practical range:

Dose: 300–600 mg per day of KSM-66, standardised to a minimum of 5% withanolides. The 300 mg twice daily protocol (600 mg total) used in several trials provides the most complete evidence base.
Timing: With meals to minimise gastrointestinal adverse effects. Evening dosing (or a split morning/evening dose) may capitalise on the GABA-A-mediated sleep improvements.
Onset of effect: Anxiolytic and sleep benefits may become noticeable within 2–4 weeks; full cortisol normalisation and cognitive improvements appear most robustly after 6–8 weeks of continuous use.
Duration: No upper limit has been established from safety data — most trials run 8–12 weeks. Many practitioners use cycling protocols (8–12 weeks on, 4 weeks off) out of theoretical caution rather than evidence of tachyphylaxis, which has not been documented in trials.
Extract type: Prefer KSM-66 over leaf-containing or unspecified extracts for the reasons outlined above. Verify the standardisation percentage is listed on the product label.

This positions ashwagandha well in a broader adaptogenic stack. For comparison with a complementary adaptogen that acts through different primary mechanisms, see our evidence review of rhodiola rosea as a cognitive adaptogen.

Conclusion: Where the Evidence Actually Lands

Ashwagandha occupies an unusual position in the nootropic space: it has genuine randomised controlled trial data, mechanistically coherent pharmacology, and a reasonable safety profile at appropriate doses from appropriate extracts. Its primary strength is not acute cognitive enhancement — it will not sharpen focus in the way caffeine or the rhodiola rosea adaptogen stack might acutely — but rather the systematic reduction of the hormonal and neuroinflammatory conditions that erode cognitive performance under chronic stress.

The Chandrasekhar cortisol data, the McEwen hippocampal architecture framework, and the Choudhary WAIS-IV improvements together tell a consistent story: ashwagandha's cognitive benefit is substantially mediated through the reversal of stress-induced hippocampal impairment. That makes it particularly relevant for individuals in high-demand cognitive environments where chronic cortisol elevation is both likely and functionally debilitating.

For anyone building a rational, evidence-based approach to cognitive resilience, ashwagandha at 300–600 mg KSM-66 daily represents one of the better-supported options currently available outside prescription pharmacology.

References cited: Mehta et al. (2010) GABA-A modulation by withanolides; Chandrasekhar et al. (2012) J Int Soc Sports Nutr; Pratte et al. (2014) J Altern Complement Med; Langade et al. (2019) Cureus; Choudhary et al. (2017) J Diet Suppl; Calabrese et al. (2014) J Psychopharmacol; Wankhede et al. (2015) J Int Soc Sports Nutr; McEwen (2007) Physiol Rev.